Objective:To study the correlation among preoperative serum carbohydrate antigen (CA) 153, CA125 and postoperative recovery, prognosis of patients with breast cancer.Methods:A total of 126 breast cancer patients admitted to our hospital from Jan. 2022 to Jan. 2024 undergoing surgical treatment were chosen as the observation group, and 50 healthy subjects were chosen as the control group during the same period. Serum CA153 and CA125 levels in the two groups were detected. The postoperative recovery of patients in the observation group was analyzed, and the correlation among postoperative recovery indexes and preoperative serum CA153, CA125 was analyzed. Patients were followed up for 6 months after surgery, and were divided into the good prognosis group and the poor prognosis group according to whether there was tumor recurrence or metastasis. Logistic regression was used to analyze the correlation among prognosis, serum CA153, CA125 levels and clinicopathological parameters of patients with breast cancer.Results:The levels of serum CA153 and CA125 in the observation group were significantly higher than those in the control group ( t=22.31, 18.82, P<0.05) ; The first time of anal exhaust, the first time of getting out of bed and the time of hospitalization after breast cancer surgery were (11.26±2.16) h, (23.30±3.54) h and (8.26±2.20) d, respectively; Postoperative recovery indexes were significantly positively correlated with preoperative serum CA153 and CA125 levels ( r=0.33, 0.45, 0.34, 0.41, 0.36, 0.50, P<0.05) ; After 6 months of follow-up, 43 patients had recurrence and metastasis, accounting for 12.20%, which could be divided into good prognosis group ( n=111) and poor prognosis group ( n=15) . Preoperative serum CA153 and CA125 levels in good prognosis group were significantly lower than those in poor prognosis group ( t=3.75, 3.61, P<0.05) ; There were no significant differences in age, menstrual status or pathological type between the good prognosis group and the poor prognosis group ( χ2=0.45, 1.49, 0.34, P>0.05) , but there were significant differences in tumor diameter, TNM stage and lymph node metastasis between the two groups ( χ2=4.38, 5.38, 5.74, P<0.05) ; Logistic regression analysis showed that CA153 ( OR=4.669, 95% CI=1.537-14.187, P<0.05) , CA125 ( OR=2.517, 95% CI=1.622-3.904, P<0.05) , TNM stage ( OR=2.942, 95% CI=1.299-6.661, P<0.05) and lymph node metastasis ( OR=3.622, 95% CI=1.242-10.561, P<0.05) were risk factors for postoperative recurrence and metastasis of breast cancer ( P<0.05) . Conclusions:Preoperative serum CA153 and CA125 levels in patients with breast cancer are related to postoperative recovery and prognosis.

Objective:To study the correlation among preoperative serum carbohydrate antigen (CA) 153, CA125 and postoperative recovery, prognosis of patients with breast cancer.Methods:A total of 126 breast cancer patients admitted to our hospital from Jan. 2022 to Jan. 2024 undergoing surgical treatment were chosen as the observation group, and 50 healthy subjects were chosen as the control group during the same period. Serum CA153 and CA125 levels in the two groups were detected. The postoperative recovery of patients in the observation group was analyzed, and the correlation among postoperative recovery indexes and preoperative serum CA153, CA125 was analyzed. Patients were followed up for 6 months after surgery, and were divided into the good prognosis group and the poor prognosis group according to whether there was tumor recurrence or metastasis. Logistic regression was used to analyze the correlation among prognosis, serum CA153, CA125 levels and clinicopathological parameters of patients with breast cancer.Results:The levels of serum CA153 and CA125 in the observation group were significantly higher than those in the control group ( t=22.31, 18.82, P<0.05) ; The first time of anal exhaust, the first time of getting out of bed and the time of hospitalization after breast cancer surgery were (11.26±2.16) h, (23.30±3.54) h and (8.26±2.20) d, respectively; Postoperative recovery indexes were significantly positively correlated with preoperative serum CA153 and CA125 levels ( r=0.33, 0.45, 0.34, 0.41, 0.36, 0.50, P<0.05) ; After 6 months of follow-up, 43 patients had recurrence and metastasis, accounting for 12.20%, which could be divided into good prognosis group ( n=111) and poor prognosis group ( n=15) . Preoperative serum CA153 and CA125 levels in good prognosis group were significantly lower than those in poor prognosis group ( t=3.75, 3.61, P<0.05) ; There were no significant differences in age, menstrual status or pathological type between the good prognosis group and the poor prognosis group ( χ2=0.45, 1.49, 0.34, P>0.05) , but there were significant differences in tumor diameter, TNM stage and lymph node metastasis between the two groups ( χ2=4.38, 5.38, 5.74, P<0.05) ; Logistic regression analysis showed that CA153 ( OR=4.669, 95% CI=1.537-14.187, P<0.05) , CA125 ( OR=2.517, 95% CI=1.622-3.904, P<0.05) , TNM stage ( OR=2.942, 95% CI=1.299-6.661, P<0.05) and lymph node metastasis ( OR=3.622, 95% CI=1.242-10.561, P<0.05) were risk factors for postoperative recurrence and metastasis of breast cancer ( P<0.05) . Conclusions:Preoperative serum CA153 and CA125 levels in patients with breast cancer are related to postoperative recovery and prognosis.

Objective:To investigate the feasibility of multipoint core needle biopsy (CNB) at mid-stage to predict the treatment effect of neoadjuvant systemic therapy for breast cancer.Methods:A total of 67 breast cancer cases with indications of neoadjuvant systemic therapy were selected from Mar. 2021 to Nov. 2022.In the fourth cycle of neoadjuvant systemic therapy, core needle biopsy was performed at 3, 6, 9, 12 points of tumor bed and residual tumor foci of breast respectively.The results of CNB were compared with the results of routine pathology of surgery after the completion of neoadjuvant therapy. Matched biopsy and surgical specimens were compared to assess pCR. The accuracy and false negative rate (FNR) of interim pathological assessment were analyzed. The coincidence probability of interim biopsy pathology and pathology of standard surgical excision was verified.Results:The median age of enrolled patients was 49.2 years (21-69 years) .Median maximum tumor diameter before neoadjuvant systemic therapy and residual tumor diameter after neoadjuvant therapy were 40.4 mm (range 21-93mm) and 19.6 mm (range 0-41mm) respectively. A total of 28 patients achieved pCR, and the PCR rates of hormone receptor-positive and HER2-nagative,triple-negative,hormone receptor negative and HER2-positive and hormone receptor-positive and HER2-positive disease were 4/24 (16.7%) ,6/14 (42.9%) ,11/18 (61.1%) ,7/11 (63.6%), respectively. Two cases had no preoperative imaging abnormalities. The results of core needle biopsy pathology of residual tumor lesions in 55 patients were consistent with those of routine post-operation pathology.The results of core needle biopsy pathology of tumor bed of 56 patients was consistent with the routine pathology of surgery. The false negative rate of interim multipoint biopsy pathology of residual tumor foci was 17.9% (12/67). The false negative rate of tumor bed with core needle biopsy was 5.9% (4/67) .Conclusions:CNB guided under ultrasound is feasible in predicting tumor retreat situation in the tumor bed area and residual tumor foci at mid-stage of neoadjuvant therapy. Increasing the number of core needles and improving biopsy techniques may improve the accuracy of pathological evaluation of interim multipoint biopsy.